**MINUTES**

**CPIC CONFERENCE CALL**

DATE: March 4, 2021

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| CPIC guidelines in progress | CPIC guidelines in progress: * *CYP2C19*/clopidogrel update – drafting recommendations
* *SLCO1B1*/simvastatin update – evidence review underway, additional drugs and genes will be included
* *G6PD*/rasburicase update – evidence review complete, starting to draft recommendations, many more drugs will be included
* SSRI update – early stages of evidence review, will include additional genes and drugs (e.g., SNRIs)
* *MT-RNR1*/aminoglycosides guideline – out for CPIC member review, plan to submit for publication soon
 | Email Kelly (kelly.caudle@stjude.org) will feedback on the draft *MT-RNR1*/aminoglycosides guideline by Monday, March 8, 2021 |
| CPIC levels and FDA tables  | CPIC has multiple levels and grading systems, not all of which relate to level of evidence:* Gene/drug pair prescribing actionability (A, B, C, D): <https://cpicpgx.org/genes-drugs/>
* Guideline prescribing recommendations (strong, moderate, optional, none)
* Relevant findings related to prescribing recommendations, strength of evidence (high, moderate, weak)
* Allele clinical functional assignments, strength of evidence (high, moderate, weak)

Two sources of FDA PGx information: * Table of Pharmacogenomic Biomarkers in Drug Labeling – CDER: <https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling>
* Table of Pharmacogenetic Associations – CDRH:

<https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations> Slides attached with minutes. |  |